DV
Dividend Vision

OVID — Ovid Therapeutics Inc

Ovid Therapeutics Inc (OVID)

Total return is -76.9% over the past 9.3 years, 351.4 points behind SPY at 274.5%. Its deepest 1-year drawdown was 34.8%.

Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain disorders, primarily epilepsies and seizure-related neurological conditions. The company's pipeline includes OV329, a GABA-AT inhibitor in Phase 1 trials for drug-resistant epilepsies, and OV4071, a potassium-chloride cotransporter 2 activator in Phase 1 trials for psychosis in Parkinson's disease, Lewy body dementia, and acute schizophrenia; it does not currently distribute dividends. Ovid appeals to investors seeking exposure to early-stage biopharmaceutical development rather than income-focused investors.

OVID key facts

Asset type
Stock
Asset class
Equity
Last close
$2.83
Market cap
$461,001,056
Average volume
1240941.0
Beta
0.18
Payout ratio
0.0
Forward P/E
1.7918
EPS
$-0.21